{"_id": "36263141|None", "id": "36263141", "infons": {}, "passages": [{"infons": {"journal": "Front Pharmacol. 2022 Oct 3;13:1007315. doi: 10.3389/fphar.2022.1007315. ", "year": "2022", "article-id_pmc": "PMC9574100", "type": "title", "authors": "Kakoti BB, Bezbaruah R, Ahmed N"}, "offset": 0, "text": "Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues.", "sentences": [], "annotations": [{"id": "1", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "neurodegenerative diseases", "locations": [{"offset": 56, "length": 26}]}], "relations": []}, {"infons": {"type": "abstract"}, "offset": 104, "text": "Drug repositioning or repurposing is the process of discovering leading-edge indications for authorized or declined/abandoned molecules for use in different diseases. This approach revitalizes the traditional drug discovery method by revealing new therapeutic applications for existing drugs. There are numerous studies available that highlight the triumph of several drugs as repurposed therapeutics. For example, sildenafil to aspirin, thalidomide to adalimumab, and so on. Millions of people worldwide are affected by neurodegenerative diseases. According to a 2021 report, the Alzheimer's disease Association estimates that 6.2 million Americans are detected with Alzheimer's disease. By 2030, approximately 1.2 million people in the United States possibly acquire Parkinson's disease. Drugs that act on a single molecular target benefit people suffering from neurodegenerative diseases. Current pharmacological approaches, on the other hand, are constrained in their capacity to unquestionably alter the course of the disease and provide patients with inadequate and momentary benefits. Drug repositioning-based approaches appear to be very pertinent, expense- and time-reducing strategies for the enhancement of medicinal opportunities for such diseases in the current era. Kinase inhibitors, for example, which were developed for various oncology indications, demonstrated significant neuroprotective effects in neurodegenerative diseases. This review expounds on the classical and recent examples of drug repositioning at various stages of drug development, with a special focus on neurodegenerative disorders and the aspects of threats and issues viz. the regulatory, scientific, and economic aspects.", "sentences": [], "annotations": [{"id": "15", "infons": {"identifier": "MESH:D000068677", "type": "Chemical", "valid": true, "normalized": ["D000068677"], "database": "ncbi_mesh", "normalized_id": "D000068677", "biotype": "chemical", "name": "Sildenafil Citrate", "accession": "@CHEMICAL_Sildenafil_Citrate"}, "text": "sildenafil", "locations": [{"offset": 519, "length": 10}]}, {"id": "16", "infons": {"identifier": "MESH:D001241", "type": "Chemical", "valid": true, "normalized": ["D001241"], "database": "ncbi_mesh", "normalized_id": "D001241", "biotype": "chemical", "name": "Aspirin", "accession": "@CHEMICAL_Aspirin"}, "text": "aspirin", "locations": [{"offset": 533, "length": 7}]}, {"id": "17", "infons": {"identifier": "MESH:D013792", "type": "Chemical", "valid": true, "normalized": ["D013792"], "database": "ncbi_mesh", "normalized_id": "D013792", "biotype": "chemical", "name": "Thalidomide", "accession": "@CHEMICAL_Thalidomide"}, "text": "thalidomide", "locations": [{"offset": 542, "length": 11}]}, {"id": "18", "infons": {"identifier": "MESH:D000068879", "type": "Chemical", "valid": true, "normalized": ["D000068879"], "database": "ncbi_mesh", "normalized_id": "D000068879", "biotype": "chemical", "name": "Adalimumab", "accession": "@CHEMICAL_Adalimumab"}, "text": "adalimumab", "locations": [{"offset": 557, "length": 10}]}, {"id": "19", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "neurodegenerative diseases", "locations": [{"offset": 625, "length": 26}]}, {"id": "20", "infons": {"identifier": "MESH:D000544", "type": "Disease", "valid": true, "normalized": ["D000544"], "database": "ncbi_mesh", "normalized_id": "D000544", "biotype": "disease", "name": "Alzheimer Disease", "accession": "@DISEASE_Alzheimer_Disease"}, "text": "Alzheimer's disease", "locations": [{"offset": 685, "length": 19}]}, {"id": "21", "infons": {"identifier": "MESH:D000544", "type": "Disease", "valid": true, "normalized": ["D000544"], "database": "ncbi_mesh", "normalized_id": "D000544", "biotype": "disease", "name": "Alzheimer Disease", "accession": "@DISEASE_Alzheimer_Disease"}, "text": "Alzheimer's disease", "locations": [{"offset": 772, "length": 19}]}, {"id": "22", "infons": {"identifier": "MESH:D010300", "type": "Disease", "valid": true, "normalized": ["D010300"], "database": "ncbi_mesh", "normalized_id": "D010300", "biotype": "disease", "name": "Parkinson Disease", "accession": "@DISEASE_Parkinson_Disease"}, "text": "Parkinson's disease", "locations": [{"offset": 873, "length": 19}]}, {"id": "23", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "neurodegenerative diseases", "locations": [{"offset": 968, "length": 26}]}, {"id": "24", "infons": {"identifier": "9606", "type": "Species", "valid": true, "normalized": [9606], "database": "ncbi_taxonomy", "normalized_id": 9606, "biotype": "species", "name": "9606", "accession": null}, "text": "patients", "locations": [{"offset": 1147, "length": 8}]}, {"id": "25", "infons": {"identifier": "-", "type": "Chemical", "valid": false, "normalized_id": null, "biotype": "chemical"}, "text": "Kinase inhibitors", "locations": [{"offset": 1384, "length": 17}]}, {"id": "26", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "neurodegenerative diseases", "locations": [{"offset": 1523, "length": 26}]}, {"id": "27", "infons": {"identifier": "MESH:D019636", "type": "Disease", "valid": true, "normalized": ["D019636"], "database": "ncbi_mesh", "normalized_id": "D019636", "biotype": "disease", "name": "Neurodegenerative Diseases", "accession": "@DISEASE_Neurodegenerative_Diseases"}, "text": "neurodegenerative disorders", "locations": [{"offset": 1694, "length": 27}]}], "relations": []}], "relations": [{"id": "R1", "infons": {"score": "0.992", "role1": {"identifier": "MESH:D000068677", "type": "Chemical", "valid": true, "normalized": ["D000068677"], "database": "ncbi_mesh", "normalized_id": "D000068677", "biotype": "chemical", "name": "Sildenafil Citrate", "accession": "@CHEMICAL_Sildenafil_Citrate"}, "role2": {"identifier": "MESH:D001241", "type": "Chemical", "valid": true, "normalized": ["D001241"], "database": "ncbi_mesh", "normalized_id": "D001241", "biotype": "chemical", "name": "Aspirin", "accession": "@CHEMICAL_Aspirin"}, "type": "Association"}, "nodes": [{"refid": "0", "role": "1,2"}]}, {"id": "R2", "infons": {"score": "0.4929", "role1": {"identifier": "MESH:D000068879", "type": "Chemical", "valid": true, "normalized": ["D000068879"], "database": "ncbi_mesh", "normalized_id": "D000068879", "biotype": "chemical", "name": "Adalimumab", "accession": "@CHEMICAL_Adalimumab"}, "role2": {"identifier": "MESH:D013792", "type": "Chemical", "valid": true, "normalized": ["D013792"], "database": "ncbi_mesh", "normalized_id": "D013792", "biotype": "chemical", "name": "Thalidomide", "accession": "@CHEMICAL_Thalidomide"}, "type": "Association"}, "nodes": [{"refid": "1", "role": "4,3"}]}], "pmid": 36263141, "pmcid": null, "meta": {}, "date": "2022-10-03T00:00:00Z", "journal": "Front Pharmacol", "authors": ["Kakoti BB", "Bezbaruah R", "Ahmed N"], "relations_display": [{"name": "associate|@CHEMICAL_Sildenafil_Citrate|@CHEMICAL_Aspirin"}, {"name": "associate|@CHEMICAL_Adalimumab|@CHEMICAL_Thalidomide"}]}
